Treats CMV retinitis. ANDA 212234, held by Ajanta Pharma Ltd. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 212234 (Valganciclovir Hydrochloride), held by Ajanta Pharma Ltd, was first approved by FDA on Dec 26, 2019, with 3 approved supplements and 0 published complete response letters.
Valganciclovir is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.1 Adult Patients Treatment of Cytomegalovirus (CMV) Retinitis: Valganciclovir tablets, USP are indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir HydrochlorideEQ 450MG BASE · tablet;oral | Valganciclovir Hydrochloride | Rx |
| Aug 22, 2022 | Supplement 19Labeling · Standard review | Approved | None posted |
| Jun 4, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jun 4, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 26, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters